Further investigations of viral infections for both herpes simplex and herpes zoster (Figure 5 and Table 5) demonstrated a significantly higher risk of herpes simplex infection in AD patients who received JAKi selective for JAK1 or TYK2 compared to placebo, a new observation, and for AD patients who received dupilumab (IL4R). Here, IL4R is linked to herpes simplex infectious disease.